Services within lung disease (IPF)

Accelerate your drug development by exploring clinical endpoints in our bleomycin-induced and
spirometry-confirmed mouse model of IPF.

BLEO-IPF mouse

  • Lean male C57BL/6J mice on normal chow diet
  • Intratracheal instillation of bleomycin followed by 28-day study period
  • Spirometry-confirmed pulmonary dysfunction, including reduced FVC.
  • Histopathological Ashcroft scoring and morphometry
  • Therapeutic intervention

Get in touch

Please get in touch if you are interested in discussing how to get started with your study. Reach out to Director Michael Feigh mfe@gubra.dk Ph. +45 2382 9493

Gubra lung in vivo approach

We offer a rodent model of fibrotic lung diseases. Study design allows for anti-fibrotic drug testing unconfounded by anti-inflammatory effects. Clinical and preclinical endpoints are applied to improve model translatability.

 

Related Links:

Main offerings

 

  • State-of-the-art rodent spirometry equipment providing a platform for evaluation of inspiratory and expiratory capacity.
  • Biochemical assessment of collagen content and inflammation.
  • Histomorphometric assessment for fibrotic and inflammatory changes in the pulmonary tissue, including Ashcroft scoring.
  • Flow cytometry analysis of bronchoalveolar lavage fluid cells.
  • RNA sequencing and bioinformatics.
  • 3D imaging of lungs.

Get in touch

Please get in touch if you are interested in discussing how to get your study started.

Michael Feigh

Director

mfe@gubra.dk
+45 2382 9493